Tag

Ervebo

All articles tagged with #ervebo

world6 days ago•386 min saved

Congo accelerates Ebola response with 16,250-dose vaccine boost amid Bundibugyo outbreak

Congo has received 16,250 doses of the Ervebo Ebola vaccine from the WHO and partners as part of a 70,000-dose rollout to combat the fastest Ebola outbreak on record caused by the Bundibugyo virus; the vaccine—while not yet specific to Bundibugyo—may offer protection and is intended to help contain the spread as Congo reports 5,375 confirmed cases across six provinces and 2,557 deaths, with more doses expected early next week. Containment challenges include ongoing armed conflict, attacks on health workers and facilities, displacement, and weak infrastructure.

via NBC News|

#bundibugyo #congo #ebola

world9 days ago•24 min saved

Congo to Receive 70,000-Dose Ebola Vaccine Boost

The Democratic Republic of the Congo will receive 70,000 doses of the Ervebo Ebola vaccine, which has proven effective in past outbreaks, to bolster efforts to contain Ebola in the region.

via AP News|

#congo #ebola #ervebo

health18 days ago•3 min saved

DRC Ebola Outbreak Began Months Earlier Than Declared, WHO Finds

The Democratic Republic of Congo's Ebola outbreak—the fastest-growing on record—started in February, months before it was officially declared in mid-May. WHO sequencing suggests early cases were misattributed to malaria and typhoid. With 4,200 confirmed cases and at least 1,900 deaths, the Bundibugyo strain has no licensed vaccines or treatments, delaying response. WHO is pursuing Ervebo vaccine trials while Bundibugyo vaccines are in early development, amid challenges from strikes, conflict, misinformation, and displacement.

via Al Jazeera|

#bundibugyo #drc #ebola

health3 months ago•10 min saved

DRC Ebola Outbreak Pushes Bundibugyo-Specific Vaccine and Therapy Efforts

An ongoing Bundibugyo-strain Ebola outbreak in the DRC—the third-largest on record—has no approved strain-specific vaccine or treatment. The existing Zaire-targeted Ervebo vaccine may offer limited cross-protection, but data are scarce and safety in this outbreak is uncertain. New Bundibugyo-focused vaccines (including a vesicular stomatitis virus–based candidate) are in development, though clinical-grade material and human trials likely won’t be ready for six to nine months. Therapies such as remdesivir and the MBP134 monoclonal antibody cocktail show promise, but delivery and safety in the field pose challenges. Beyond vaccines and drugs, rapid diagnosis, isolation, contact tracing, and strong outbreak response remain essential tools for control.

via CNN|

#bundibugyo #ebola #ervebo